Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT05817331
Registration number
NCT05817331
Ethics application status
Date submitted
4/04/2023
Date registered
18/04/2023
Titles & IDs
Public title
Refine and Assess the Readability of Patient, Carer, and Clinician Treatment Preference in Myelodysplasia Questionnaire
Query!
Scientific title
Qualitative Interviews to Refine and Assess the Importance of Constructs, and Ensure the Readability of Patient, Carer, and Clinician Versions of the Treatment Preference in Myelodysplasia Questionnaire (TPMQ): pTPMQ, cTPMQ, and mTPMQ, Respectively
Query!
Secondary ID [1]
0
0
2021_PID02858
Query!
Secondary ID [2]
0
0
393-419-00045
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
TPMQ
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Myelodysplastic Syndrome (MDS)
0
0
Query!
Condition category
Condition code
Blood
0
0
0
0
Query!
Haematological diseases
Query!
Blood
0
0
0
0
Query!
Other blood disorders
Query!
Intervention/exposure
Study type
Observational
Query!
Patient registry
Query!
Target follow-up duration
Query!
Target follow-up type
Query!
Description of intervention(s) / exposure
Other interventions - Carer Treatment Preference Myelodysplasia Questionnaire
Other interventions - Clinician Treatment Preference Myelodysplasia Questionnaire
Other interventions - Patient Treatment Preference Myelodysplasia Questionnaire
Patient - Patients with MDS
Carer - Carers of patients with MDS
Clinician - Clinicians who treat MDS
Other interventions: Carer Treatment Preference Myelodysplasia Questionnaire
Caregiver-reported outcome measure in MDS
Other interventions: Clinician Treatment Preference Myelodysplasia Questionnaire
Clinician-reported outcome measure in MDS
Other interventions: Patient Treatment Preference Myelodysplasia Questionnaire
Patient-reported outcome measure (PROM) in MDS
Query!
Intervention code [1]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Validation of the pTPMQ, cTPMQ and mTPMQ
Query!
Assessment method [1]
0
0
Observational qualitative study consisting of interviews with MDS participants. The study endpoints are an assessment of understanding of the questions, response options and directions, as described in the ISPOR patient-reported outcome measure (PROM) guidance.
Query!
Timepoint [1]
0
0
Each participant is interviewed once for approximately 45 - 60 minutes
Query!
Eligibility
Key inclusion criteria
Potential subjects must satisfy all of the following criteria to be enrolled in the study:
A. Adult patients with myelodysplastic syndrome meeting any one of the following criteria:
1. They are currently being treated with azacitidine or
2. They have recently been treated with azacitidine or
3. They have been deemed eligible for treatment with azacitidine, but have not yet commenced treatment
B: Primary caregiver of a patient meeting all of the inclusion criteria (i.e. a patient who meets criteria defined above in A).
C. Clinician treating patients meeting all of the inclusion criteria (i.e. treats patients who meet criteria defined above in A).
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Potential subjects who meet any of the following criteria will be excluded from participating in the study:
Exclusion Criteria
A. Patients meeting any of the following criteria are excluded:
1. They have lower risk disease (international prognostic scoring system low or intermediate-1 risk)
2. Cognitive or physical impairment of a nature that makes it infeasible for them to effectively participate in a structured interview.
3. Deemed appropriate for stem cell transplantation and are being pre-treated or will be treated with azacitidine
4. They were treated, are being treated, or will be treated with azacitdine as part of a clinical trial
5. They are a relative of an employee of the investigational clinic, sponsor or research organization (e.g., Investigator, Coordinator, Technician, Interviewer).
B. Carers meeting any of the following criteria are excluded:
1. They are a caregiver of a patient who meets any of the exclusion criteria listed above in A
2. They are a relative of an employee of the investigational clinic, sponsor or research organization (e.g., Investigator, Coordinator, Technician, Interviewer).
C. Clinician will be excluded from participating in the study if a relative of an employee of the sponsor or research organization (e.g., Investigator, Coordinator, Technician, Interviewer).
D. Participants who are not fluent in English, or who cannot read or write in English will be excluded from the study
Query!
Study design
Purpose
Query!
Duration
Query!
Selection
Query!
Timing
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
28/06/2022
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
10/03/2023
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
16
Query!
Recruitment in Australia
Recruitment state(s)
NSW
Query!
Recruitment hospital [1]
0
0
Calvary Mater Newcastle - Newcastle
Query!
Recruitment postcode(s) [1]
0
0
- Newcastle
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Otsuka Australia Pharmaceutical Pty Ltd
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The primary goal of this study is to use qualitative interviews to elicit and confirm concepts related to treatment preferences and understandability of the pTPMQ, cTPMQ, and mTPMQ. The information gathered will be used to support the appropriateness of the questionnaires as a patient-reported, caregiver-reported and clinician-reported outcome measure (PROM) in the population of interest.
Query!
Trial website
https://clinicaltrials.gov/study/NCT05817331
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Anoop K Enjeti, MBBS FRCP FRCPA PhD
Query!
Address
0
0
Calvary Mater Newcastle, Edith Street, Waratah, NSW 2298 Australia
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT05817331